...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of colorectal disease. >HER-2eu overexpression is an independent prognostic factor in colorectal cancer.
【24h】

HER-2eu overexpression is an independent prognostic factor in colorectal cancer.

机译：HER-2 / neu过表达是结直肠癌的独立预后因素。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND AIMS: The HER-2eu protein is intimately involved with normal cell proliferation and tissue growth, as it is extensively homologous and is related to the epidermal growth factor receptor. This phenomenon has been most intensively studied in the context of breast carcinoma, in which its amplification and overexpression correlate with the overall course of disease and poor prognoses, and also constitute a predictive factor of poor response to chemotherapy and endocrine therapy. In this study, we investigated the relationships between the expression of HER-2eu and the clinicopathological characteristics of colorectal cancer, including survival. This study was performed with a view toward the future introduction of Herceptin therapy for colorectal cancer patients. PATIENTS AND METHODS: HER-2eu overexpression and gene amplification were examined via semiquantitative standardized immunohistochemical staining and fluorescence in situ hybridization (FISH) in 137 colorectal cancer patients who underwent curative surgery at the Kangbuk Samsung Hospital. RESULTS: Sixty-five (47.4%) out of 137 patients were determined by immunohistochemistry to have overexpressed HER-2eu protein. HER-2eu gene amplification was detected in two patients by FISH. Tumors with HER-2eu overexpression showed higher postoperative recurrence rate (39.3% vs 14.6%, p=0.013). Tumors with HER-2eu overexpression were associated with poor 3-year (70.8% vs 83.7%) and 5-year survival rates (55.1% vs 78.3%, p<0.05). Advanced TNM stage, postoperative recurrence, and overexpression of HER-2eu were found to be independently related to survival by multivariate analysis. CONCLUSION: HER-2eu overexpression may constitute an independent prognostic factor in colorectal cancer patients, and patients exhibiting HER-2eu overexpression might constitute potential candidates for a new adjuvant therapy which involves the use of humanized monoclonal antibodies.
机译：背景与目的：HER-2 / neu蛋白与广泛的同源性并与表皮生长因子受体有关，与正常细胞增殖和组织生长密切相关。在乳腺癌的背景下，对该现象进行了最深入的研究，在乳腺癌中，其扩增和过度表达与疾病的整体进程和预后不良相关，并且还构成了对化学疗法和内分泌疗法反应不良的预测因素。在这项研究中，我们调查了HER-2 / neu的表达与结直肠癌的临床病理特征（包括生存）之间的关系。进行这项研究的目的是为了将来为大肠癌患者引入赫赛汀疗法。病人和方法：通过半定量标准化免疫组织化学染色和荧光原位杂交（FISH）检查了137位在江北三星医院接受根治性手术的结直肠癌患者的HER-2 / neu过表达和基因扩增。结果：137例患者中有65例（47.4％）通过免疫组织化学确定了HER-2 / neu蛋白过表达。通过FISH在两名患者中检测到HER-2 / neu基因扩增。 HER-2 / neu过表达的肿瘤术后复发率更高（39.3％vs 14.6％，p = 0.013）。 HER-2 / neu过表达的肿瘤与3年生存率较低（70.8％对83.7％）和5年生存率相关（55.1％对78.3％，p <0.05）。通过多变量分析发现，晚期TNM分期，术后复发和HER-2 / neu过度表达与生存独立相关。结论：HER-2 / neu过表达可能构成结直肠癌患者的独立预后因素，而表现出HER-2 / neu过表达的患者可能构成涉及使用人源化单克隆抗体的新辅助疗法的潜在候选人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号